This report identifies the generalized anxiety disorder market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to generalized anxiety disorder market.
Globally North America dominated the market for generalized anxiety disorder in 2015 with highest market share due to higher research and development activities by pharmaceutical industry in the region. North America was followed by Europe as the second largest regional market for generalized anxiety disorder due to higher patients complaining about stressful life style resulting into GAD. However, Asia-Pacific is expected to remain fastest growing regional segment during the period of study due to changing life style and increasing awareness about such diseases in the region.
This report on global generalized anxiety disorder covers different therapeutics type of generalized anxiety disorder, market size in various geographical regions.
On the basis of therapeutics type of generalized anxiety disorder, this report also covers all the major therapeutics types of generalized anxiety disorder major types covered in this report are as follows: Antidepressant (Selective serotonin reuptake inhibitor (SSRI) and Serotonin norepinephrine reuptake inhibitor(SNRI)), Benzodiazepines (Alprazolam, Chlordiazepoxide, Diazepam, Lorazepam) and Others (Buspirone)
This is report has been further segmented into major regions, which includes detailed analysis of each region such as North America, Europe, Asia-Pacific (APAC) and Rest of the World (RoW) covering all the major country level markets for generalized anxiety disorder in each of the region.
This report identifies all the major companies operating in the global generalized anxiety disorder market. Some of the major companies’ profiles in detail are as follows:
GlaxoSmithKline Pharmaceuticals Limited
Sumitomo Dainippon Pharma
Noven Pharmaceuticals, Inc.
Actavis Pharmaceutical Company
Please Note: The report is to be delivered in 1-2 working days after an order is placed.
2. Executive Summary
3. Market Landscape
3.1. Market Share Analysis
3.2. Comparative Analysis
3.2.1. Product Benchmarking
3.2.2. End User Profiling
3.2.3. Top 5 Financials Analysis
4. Generalized Anxiety Disorder – Market Forces
4.1.1. Increasing reported cases of HIV, Cancer and cystic fibrosis
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Degree of Competition
5. Generalized Anxiety Disorder – Strategic Analysis
5.1. Value Chain Analysis
5.2. Pricing Analysis
5.3. Opportunities Analysis
5.4. Product/Market Life Cycle Analysis
5.5. Suppliers and Distributors
6. Generalized Anxiety Disorder Market, By Therapeutics Type
6.1.1. Selective serotonin reuptake inhibitor (SSRI)
6.1.2. Serotonin norepinephrine reuptake inhibitor(SNRI)
6.3. Others (Buspirone)
7. Generalized Anxiety Disorder Market, By Geography
7.1.7. Rest of Europe
7.2. Asia Pacific
7.2.4. South Korea
7.2.5. Rest of Asia-Pacific
7.3. North America
7.4. Rest of the World (RoW)
7.4.2. Rest of RoW
8. Generalized Anxiety Disorder – Market Entropy
8.2. Technological Developments
8.3. Merger & Acquisitions, and Joint Ventures
8.4. Supply- Contract
9. Company Profiles (Introduction, Financials, Key Insights, Key Strategy, Product Portfolio, SWOT Analysis)
9.1. GlaxoSmithKline Pharmaceuticals Limited
9.2. Bristol-Myers Squibb
9.3. Sumitomo Dainippon Pharma
9.4. Noven Pharmaceuticals, Inc.
9.5. Actavis Pharmaceutical Company
9.6. F. Hoffmann-La Roche
9.7. Abbott Laboratories
9.8. Eli Lilly and Company
9.9. Pfizer, Inc.
9.10. Shionogi and Company
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
10.3. Research Methodology
10.4. Expert Insights